Skip to main content
SpringerLink
Log in

A Markov Process Analysis Comparing the Cost Effectiveness of Maintenance Therapy with Citalopram versus Standard Therapy in Major Depression

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

The objective of this study was to demonstrate the cost effectiveness of long term maintenance treatment with citalopram versus standard therapy (defined as short term antidepressant treatment) in patients with major depression in Germany. We chose doxepin, amitriptyline and trimipramine as standard therapy because these drugs are the leading antidepressants in that country. A Markov process analysis was used to model health status and economic outcomes as they accrued over a 1-year follow-up period. The main outcome measures were time without depression, direct costs and indirect costs (work days lost). All costs were in 1993 Deutschmarks. The clinical data were obtained from the published literature and US clinical practice guidelines; the associated unit costs of the medical resources used were derived from official German tariff lists. The results show that, compared with standard therapy, long-term maintenance treatment with citalopram is associated with a mean increase in time without depression of 7.9% (8.2 vs 7.6 months). The total costs of maintenance treatment with citalopram were substantially lower than with standard therapy (DM7985 vs DM11 948 per patient per year. In addition, both the direct and indirect costs of maintenance treatment with citalopram (DM3764 vs DM4221 per patient, respectively) were lower than with standard therapy (DM4577 vs DM7371 per patient, respectively). In conclusion, the study demonstrates that one year’s maintenance treatment with citalopram is both more effective and less costly than standard therapy in the treatment of patients with major depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brown GW, Craig TKJ, Harris TO. Depression: distress or disease? Some epidemiological considerations. Br J Psychiatry 1985; 147: 612–22

    Article  PubMed  CAS  Google Scholar 

  2. Regier DA, Myers JK, Kramer M, et al. The NIMH epidemiological catchment area program. Arch Gen Psychiatry 1984; 41 (10): 934–41

    Article  PubMed  CAS  Google Scholar 

  3. Myers JK, Weissman MM, Tischler GL, et al. Six-month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry 1984; 41: 959–67

    Article  PubMed  CAS  Google Scholar 

  4. Perris C. The course of depressive psychoses. Acta Psychiatr Scand 1968; 44: 238–48

    Article  PubMed  CAS  Google Scholar 

  5. Angst J. The epidemiology of depression. Psychopharmacology 1992; 106 Suppl.: 71–4

    Article  Google Scholar 

  6. Carlson GA, Kotin JL, Davenport XB, et al. Follow-up of 53 bipolar manic-depressive patients. Br J Psychiatry 1990; 124: 134–9

    Article  Google Scholar 

  7. Lehmann HE, Fenton FR, Deutch M, et al. An 11-year follow-up of 110 depressed patients. Acta Psychiatr Scand 1988; 78: 57–65

    Article  PubMed  CAS  Google Scholar 

  8. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387–94

    Article  PubMed  CAS  Google Scholar 

  9. Thase ME. Relapse and recurrences in unipolar depression: short-term and long-term approaches. J Clin Psychiatry 1990; 51 Suppl.: 51–7

    PubMed  Google Scholar 

  10. Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67–76

    Article  PubMed  CAS  Google Scholar 

  11. Clinical practice guideline. Depression in primary care: treatment of major depression (AHCPR publication no. 93–0551). Rockville (MD): Public Health Service, Agency for Health Care Policy and Research, 1993

  12. WHO Mental Health Collaborating Centres. Pharmacotherapy of depressive disorders: a consensus statement. J Affect Disord 1989; 17: 197–8

    Article  Google Scholar 

  13. Montgomery SA, Dunbar GC. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993; 8: 189–95

    Article  PubMed  CAS  Google Scholar 

  14. National Institute of Mental Health. A consensus development conference statement. Mood disorders: pharmacological prevention ofrecurrence. Am J Psychiatry 1985; 142: 469–76

    Google Scholar 

  15. Frank E, Kupfer DJ, Wagner EF, et al. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: contributing factors. Arch Gen Psychiatry 1991; 48: 1053–9

    Article  PubMed  CAS  Google Scholar 

  16. Klerman GL, Weissman MM. The course, morbidity and costs of depression. Arch Gen Psychiatry 1992; 49: 831–4

    Article  PubMed  CAS  Google Scholar 

  17. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143: 18–23

    PubMed  CAS  Google Scholar 

  18. Schou M, Thomsen K, Baastrup PC. Studies on the course of recurrent endogenous affective disorders. Int Pharmacopsychiatry 1970; 5: 100–6

    Google Scholar 

  19. Montgomery SA. Failure to demonstrate prophylactic efficacy of dothiepin. Br J Psychiatry 1993; 163: 257–8

    Article  PubMed  CAS  Google Scholar 

  20. Kupfer DF, Frank E, Perel LM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73

    Article  PubMed  CAS  Google Scholar 

  21. Baastrup PC, Poulsen IC, Schou M. Prophylactic lithium: double- blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; 2: 326–30

    Article  PubMed  CAS  Google Scholar 

  22. Montgomery SA, Dufour H, Brion S. The prophylactic effect of f1uoxetine in unipolar depression. Br J Psychiatry 1988; 153 Suppl. 3: 69–76

    Google Scholar 

  23. Montgomery SA, Rasmussen JGC, Tanghoi P. A 24-week study of 20mg citalopram, 40mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 9: 181–8

    Article  Google Scholar 

  24. Souêtre E, Martin P. Clinical economics and psychiatry. In: The use of f1uoxetine in clinical practice. Royal Society of Medicine Publications, 1991: 67–73

    Google Scholar 

  25. McGuire TG. Measuring the economic costs of schizophrenia. Schizophr Bull 1991; 17 (3): 375–88

    Article  PubMed  CAS  Google Scholar 

  26. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. Public Health Rep 1991; 103 (3): 280–92

    Google Scholar 

  27. McCombs JS, Nichol MB, Stimmel GL. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a medical population. J Clin Psychiatry 1990; 51 (6 Suppl.): 60–9

    PubMed  Google Scholar 

  28. Greenberg PE, Stiglin LE, Findelstein SN, et al. The economic burden of depression. J Clin Psychiatry 1993; 54: 405–18

    PubMed  CAS  Google Scholar 

  29. Souêtre E. Arrêt de travail et depression: impact de la f1uoxetine. Therapie 1993; 48: 81–8

    PubMed  Google Scholar 

  30. Souêtre E, Qing W, Hardens M. Methodological approaches to pharmacoeconomics. Fundam Clin Pharmacol 1994; 8: 101–7

    Article  PubMed  Google Scholar 

  31. Hertzman P. The economic costs of mental illness in Sweden 1975. Acta Psychiatr Scand 1983; 68: 359–67

    Article  PubMed  CAS  Google Scholar 

  32. Andrews G, Hall W, Goldstein G, et al. The economic costs of schizophrenia. Arch Gen Psychiatry 1985; 42: 537–43

    Article  PubMed  CAS  Google Scholar 

  33. Hay J, Ernst R. The economic costs of Alzheimer’s disease. Am J Public Health 1987; 77: 1169–75

    Article  PubMed  CAS  Google Scholar 

  34. Boston Consulting Group. The contribution of pharmaceutical companies. Boston: Boston Consulting Group, 1993: 149–50

    Google Scholar 

  35. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264 (19): 2524–8

    Article  PubMed  CAS  Google Scholar 

  36. Schurman RA, Kramer PD, Mitchell JB. The hidden mental health network. Arch Gen Psychiatry 1985; 42: 89–94

    Article  PubMed  CAS  Google Scholar 

  37. Wells KB, Hays RD, Burnam MA, et al. Detection of depressive disorder for patients receiving prepaid or fee-for-service care. JAMA 1989; 262: 3298–302

    Article  PubMed  CAS  Google Scholar 

  38. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. PharmacoEconomics 1994; 5 (3): 249–64

    Article  PubMed  CAS  Google Scholar 

  39. Weinstein MC, Fineberg HY. Clinical decision analysis. Philadelphia (PA): WB Saunders Co., 1980: 228–65

    Google Scholar 

  40. Beck JR, Paulker SG. The Markov process in medical diagnosis. Med Decis Making 1983; 3 (4): 419–58

    Article  PubMed  CAS  Google Scholar 

  41. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 163: 92/94/1–10

    Google Scholar 

  42. Rosenberg C, Damsbo N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice: a Nordic multicentre clinical study. Int Clin Psychopharmacol 1994; 9 Suppl. 1: 41–8

    Article  PubMed  Google Scholar 

  43. BMA. Bewertungsmass-stab für kassenärtzliche Leistungen. Cologne: Deutscher Arzte-Verlag GmbH, 1993

    Google Scholar 

  44. Rote Liste 1993. Arzneimittelverzeichnis des BPI. Aulendorf/ Würtemberg: Edition Cantor Verlag für Medizin und Naturwissenschaften GmbH, 1993

  45. DOK-8: AOK-Bundesverband, 1994 Apr 15: 256

    Google Scholar 

  46. Statistisches Jahrbuch für die Bundesrepublik Deutschland 1993. Kusterdingen: Verlag Metzler-Poeschel, 1993

  47. Boyer W, Feighner JP. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Jonsson B, Rosenbaum J, editors. Health economics of depression. Chichester: Wiley, 1993: 65–76

    Google Scholar 

  48. Schubert F. Ontario guidelines for economic analysis of pharmaceutical products. Ottawa: Ministry of Health, Drug Programs Branch, 1993

    Google Scholar 

  49. Schubert F, editor. Proceedings of the Canadian Collaborative Workshop on Pharmacoeconomics. Princeton (NJ): Excerpta Medica, Inc., 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Benefit Research Group, Schipholweg 9F, 2316 XB, Leiden, The Netherlands

    Mark J. C. Nuijten

  2. Benefit Research Group, Paris, France

    Martin Hardens

  3. Benefit Research Group, Cambridge, Massachusetts, USA

    Eric Souêtre

Authors
  1. Mark J. C. Nuijten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Hardens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Souêtre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nuijten, M.J.C., Hardens, M. & Souêtre, E. A Markov Process Analysis Comparing the Cost Effectiveness of Maintenance Therapy with Citalopram versus Standard Therapy in Major Depression. Pharmacoeconomics 8, 159–168 (1995). https://doi.org/10.2165/00019053-199508020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199508020-00007

Keywords

Search

Navigation